Literature DB >> 35245430

Effects of Vitamin D Serum Level on Morbidity and Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis.

Yiyun Hu1, Janice Kung2, Andrew Cave3, Hoan Linh Banh4.   

Abstract

PURPOSE: It has been shown that low Vitamin D serum concentration is associated with increased pneumonia and viral respiratory infections. Vitamin D is readily available, inexpensive, and easy to administer to subjects infected with COVID-19. If effective in reducing the severity of COVID-19, it could be an important and feasible therapeutic intervention.
METHODS: We performed a systematic review and meta-analysis of the literature to determine the effects of Vitamin D serum concentration on mortality and morbidity in COVID-19 patients. The primary objectives were to determine if Vitamin D serum concentration decrease mortality, ICU admissions, ventilator support, and length of hospital stay in COVID-19 patients.
RESULTS: A total of 3572 publications were identified. Ultimately, 20 studies are included. A total of 12,806 patients aged between 42 to 81 years old were analyzed. The pooled estimated RR for mortality, ICU admission, ventilator support and length of hospital stay were 1.49 (95% CI: 1.34, 1.65), 0.87 (95% CI: 0.67, 1.14), 1.29 (95% CI: 0.79, 1.84), and 0.84 (95% CI -0.45, 2.13).
CONCLUSION: There is no statistical difference in mortality, ICU admission rate, ventilator support requirement, and length of hospital stay in COVID-19 patients with low and high Vitamin D serum concentration.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35245430     DOI: 10.18433/jpps32590

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  2 in total

1.  Vitamin D Supplementation and COVID-19 Outcomes: Mounting Evidence and Fewer Doubts.

Authors:  Arrigo F G Cicero; Federica Fogacci; Claudio Borghi
Journal:  Nutrients       Date:  2022-08-31       Impact factor: 6.706

Review 2.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.